
On Friday, Novo Nordisk announced in a company statement that it has once again applied to the US Food and Drug Administration (FDA) for permission to start marketing the weekly diabetes treatment Ozempic in a higher dosage.
In February, the FDA declined to start processing a previous application since the health authority lacked information on factors such as a new production facility before granting the necessary approvals. Instead, the FDA sent a Refusal to File Letter in March.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app